Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more
Xvivo Perfusion AB (publ) (XVIPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.041x
Based on the latest financial reports, Xvivo Perfusion AB (publ) (XVIPF) has a cash flow conversion efficiency ratio of 0.041x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($86.71 Million) by net assets ($2.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xvivo Perfusion AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Xvivo Perfusion AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xvivo Perfusion AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xvivo Perfusion AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rupert Resources Ltd
OTCQX:RUPRF
|
-0.002x |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
0.036x |
|
GungHo Online Entertainment Inc
OTCGREY:GUNGF
|
1.127x |
|
SandRidge Energy Inc
NYSE:SD
|
0.062x |
|
Salfacorp
SN:SALFACORP
|
0.128x |
|
Hunan New Wellful Co Ltd
SHG:600975
|
0.064x |
|
Wiscom System Co Ltd
SHE:002090
|
0.073x |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
0.174x |
Annual Cash Flow Conversion Efficiency for Xvivo Perfusion AB (publ) (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xvivo Perfusion AB (publ) from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.11 Billion | $100.81 Million | 0.048x | -7.33% |
| 2024-12-31 | $2.16 Billion | $111.29 Million | 0.052x | +116.83% |
| 2023-12-31 | $1.95 Billion | $46.29 Million | 0.024x | +22.18% |
| 2022-12-31 | $1.43 Billion | $27.86 Million | 0.019x | +307.63% |
| 2021-12-31 | $1.29 Billion | $-12.06 Million | -0.009x | +22.87% |
| 2020-12-31 | $1.01 Billion | $-12.27 Million | -0.012x | -123.81% |
| 2019-12-31 | $577.52 Million | $29.50 Million | 0.051x | +16.87% |
| 2018-12-31 | $540.48 Million | $23.63 Million | 0.044x | -0.64% |
| 2017-12-31 | $504.33 Million | $22.19 Million | 0.044x | +10.93% |
| 2016-12-31 | $316.41 Million | $12.55 Million | 0.040x | -14.52% |
| 2015-12-31 | $184.87 Million | $8.58 Million | 0.046x | +318.52% |
| 2014-12-31 | $176.18 Million | $-3.74 Million | -0.021x | -115.24% |
| 2013-12-31 | $96.64 Million | $13.46 Million | 0.139x | +641.01% |
| 2012-12-31 | $88.77 Million | $1.67 Million | 0.019x | -- |